S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
NASDAQ:CORT

Corcept Therapeutics - CORT Stock Forecast, Price & News

$24.32
-0.15 (-0.61%)
(As of 02/3/2023 09:03 PM ET)
Add
Compare
Today's Range
$23.93
▼
$24.87
50-Day Range
$19.95
▼
$25.56
52-Week Range
$17.19
▼
$30.14
Volume
611,700 shs
Average Volume
612,104 shs
Market Capitalization
$2.62 billion
P/E Ratio
24.32
Dividend Yield
N/A
Price Target
$31.67

Corcept Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
30.2% Upside
$31.67 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.06
Upright™ Environmental Score
News Sentiment
0.86mentions of Corcept Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.04 M Sold Last Quarter
Proj. Earnings Growth
2.25%
From $0.89 to $0.91 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Medical Sector

57th out of 1,025 stocks

Pharmaceutical Preparations Industry

21st out of 498 stocks

See Top Rated MarketRank™ Stocks Here
CORT stock logo

About Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CORT Stock News Headlines

February 1, 2023 | americanbankingnews.com
Corcept Therapeutics (NASDAQ:CORT) Rating Lowered to Buy at StockNews.com
January 24, 2023 | finance.yahoo.com
Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)
February 6, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
January 17, 2023 | finance.yahoo.com
Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe
January 11, 2023 | finance.yahoo.com
Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?
January 8, 2023 | seekingalpha.com
Corcept Therapeutics: Korlym Overhang Appears To Be A Drag On Valuation Upside
January 1, 2023 | benzinga.com
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation - CORT
December 29, 2022 | finance.yahoo.com
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
February 6, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
December 28, 2022 | marketwatch.com
EQUITY ALERT: Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation – CORT
December 20, 2022 | finance.yahoo.com
Why Corcept Therapeutics (CORT) is a Top Growth Stock for the Long-Term
December 8, 2022 | finance.yahoo.com
Corcept Therapeutics Provides Miricorilant Clinical Development Update
December 8, 2022 | finance.yahoo.com
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
November 24, 2022 | benzinga.com
Corcept Therapeutics Chief Business Officer Sold $130K In Company Stock
November 22, 2022 | benzinga.com
Corcept Therapeutics Chief Business Officer Trades Company's Stock
November 16, 2022 | finance.yahoo.com
Here's Why Corcept Therapeutics (CORT) is a Strong Growth Stock
November 2, 2022 | msn.com
Corcept Therapeutics's Earnings: A Preview
October 21, 2022 | finance.yahoo.com
These 3 Stocks Are Winning the Bear Market -- Here's How
October 20, 2022 | finance.yahoo.com
Corcept (CORT) Thrives on Korlym, Overdependence a Concern
October 18, 2022 | finance.yahoo.com
Corcept Therapeutics (NASDAQ:CORT) jumps 6.8% this week, though earnings growth is still tracking behind three-year shareholder returns
October 13, 2022 | marketwatch.com
Corcept Therapeutics Initiates DAZALS - A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
October 11, 2022 | finance.yahoo.com
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
October 10, 2022 | nasdaq.com
Insiders sold US$2.0m worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) stock last year, could be a warning sign to watch out for
September 3, 2022 | nasdaq.com
Corcept Therapeutics' (NASDAQ:CORT) earnings growth rate lags the 26% CAGR delivered to shareholders
September 2, 2022 | finance.yahoo.com
Corcept (CORT) Down 8.3% Since Last Earnings Report: Can It Rebound?
August 25, 2022 | finance.yahoo.com
ASRT or CORT: Which Is the Better Value Stock Right Now?
August 21, 2022 | finance.yahoo.com
Do Corcept Therapeutics' (NASDAQ:CORT) Earnings Warrant Your Attention?
See More Headlines
Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CORT Company Calendar

Last Earnings
11/03/2021
Today
2/06/2023
Next Earnings (Estimated)
2/21/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:CORT
CUSIP
21835210
CIK
1088856
Web
www.corcept.com
Phone
(650) 327-3270
Fax
650-327-3218
Employees
238
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$31.67
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+30.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$1.00
Trailing P/E Ratio
24.32
Forward P/E Ratio
27.33
P/E Growth
N/A
Net Income
$112.51 million
Net Margins
29.37%
Pretax Margin
32.35%
Return on Equity
27.49%
Return on Assets
24.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.52
Quick Ratio
8.41

Sales & Book Value

Annual Sales
$365.98 million
Price / Sales
7.15
Cash Flow
$1.00 per share
Price / Cash Flow
24.29
Book Value
$3.26 per share
Price / Book
7.46

Miscellaneous

Outstanding Shares
107,650,000
Free Float
87,627,000
Market Cap
$2.62 billion
Optionable
Optionable
Beta
0.55

Social Links


Key Executives

  • Joseph K. Belanoff
    President, Chief Executive Officer & Director
  • Atabak Mokari
    Chief Financial Officer
  • Hazel Hunt
    Chief Scientific Officer
  • Sean MaduckSean Maduck
    President-Corcept Endocrinology
  • William Guyer
    Chief Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CORT Stock - Frequently Asked Questions

Should I buy or sell Corcept Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CORT shares.
View CORT analyst ratings or view top-rated stocks.

What is Corcept Therapeutics' stock price forecast for 2023?

3 Wall Street analysts have issued twelve-month price targets for Corcept Therapeutics' stock. Their CORT share price forecasts range from $30.00 to $35.00. On average, they anticipate the company's share price to reach $31.67 in the next twelve months. This suggests a possible upside of 30.2% from the stock's current price.
View analysts price targets for CORT or view top-rated stocks among Wall Street analysts.

How have CORT shares performed in 2023?

Corcept Therapeutics' stock was trading at $20.31 at the beginning of the year. Since then, CORT shares have increased by 19.7% and is now trading at $24.32.
View the best growth stocks for 2023 here.

When is Corcept Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our CORT earnings forecast.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) issued its earnings results on Wednesday, November, 3rd. The biotechnology company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.19 by $0.05. The biotechnology company had revenue of $96.13 million for the quarter, compared to analyst estimates of $97.75 million. Corcept Therapeutics had a net margin of 29.37% and a trailing twelve-month return on equity of 27.49%. During the same quarter in the previous year, the company earned $0.17 EPS.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $400.00 million-$410.00 million, compared to the consensus revenue estimate of $416.67 million.

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (6.34%), Boston Trust Walden Corp (1.72%), FAS Wealth Partners (0.28%), Bank of Montreal Can (0.17%), Allspring Global Investments Holdings LLC (0.13%) and State of Alaska Department of Revenue (0.06%). Insiders that own company stock include Daniel N Swisher Jr, G Leonard Baker Jr, G Leonard Baker, Jr, Gary Charles Robb, Joseph Douglas Lyon, Joseph K Belanoff and Sean Maduck.
View institutional ownership trends.

How do I buy shares of Corcept Therapeutics?

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $24.32.

How much money does Corcept Therapeutics make?

Corcept Therapeutics (NASDAQ:CORT) has a market capitalization of $2.62 billion and generates $365.98 million in revenue each year. The biotechnology company earns $112.51 million in net income (profit) each year or $1.00 on an earnings per share basis.

How many employees does Corcept Therapeutics have?

The company employs 238 workers across the globe.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The official website for the company is www.corcept.com. The biotechnology company can be reached via phone at (650) 327-3270, via email at cjames@corcept.com, or via fax at 650-327-3218.

This page (NASDAQ:CORT) was last updated on 2/6/2023 by MarketBeat.com Staff